- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT07946367
Dual-targeting of B & T Cell Pathways Evaluation Trial (DUET)
Evaluation of Safety, Treatment Response and Biological Effects of DFI205 in Systemic Autoimmune Rheumatic Diseases (SARDs); a Phase 1/2a First-in-Human (FIH) Study
This is a first-in-human study of DFI205, an investigational bispecific antibody that binds CD20 and CD40, with the goal of targeting both B- and T-cell function in adults with active systemic autoimmune rheumatic diseases (SARDs) despite standard therapy. In Phase 1, participants with RA, SLE, SSc or IIM will receive a single dose at increasing dose levels to establish safety and initial treatment response. The selected dose will be carried forward into Phase 2a, where participants will receive monthly doses to assess safety and treatment response.
Studienübersicht
Status
Bedingungen
Intervention / Behandlung
Studientyp
Einschreibung (Geschätzt)
Phase
- Phase 2
- Phase 1
Kontakte und Standorte
Studienkontakt
- Name: Bernhard Remes
- Telefonnummer: 0049641944360
- E-Mail: info@diabetesfree.com
Studienorte
-
-
-
Erlangen, Deutschland, 91054
- Rekrutierung
- Universitaetsklinikum Erlangen AöR
-
Kontakt:
- Georg Schett
- Telefonnummer: 00499131-85-32093
- E-Mail: Studienambulanz.M3@uk-erlangen.de
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
- Male and female participants, age 18 years and older.
- Able to understand and comply with all scheduled visits, treatment plans, laboratory tests, and other procedures of the study protocol including ability to provide written informed consent.
- Maintaining a stable, qualifying, standard of care regimen for ≥4 weeks prior to screening as treatment for a qualifying primary diagnosis (RA, SLE, SSc, IIM including the disease-specific criteria listed below):
- Rheumatoid Arthritis (RA) participants must have, 1) positivity of anti-citrullinated protein antibody (ACPA) and/or rheumatoid factor (RF); 2) moderate to highly active disease despite treatment with at least 2 lines of standard therapy; 3) disease duration ≥ 6 months; secondary Sjögren's disease diagnosis is acceptable as long as other criteria are met.
- Systemic Lupus Erythematosus (SLE) participants must have, 1) positivity of anti-nuclear-antibodies (ANA) and/or anti-dsDNA and/or anti-histone and/or anti-nucleosome and/or anti-Sm antibodies; 2) active disease despite treatment with at least 2 lines of standard therapy; 3) disease duration ≥ 6 months.
- Systemic Sclerosis (SSc) participants must have, 1) positivity for at least one SSc-associated autoantibody; 2) mRSS score >10 units or interstitial lung disease (ILD) including clinically relevant pulmonary involvement despite treatment with at least 2 lines of standard therapy; 3) disease duration ≤ 5 years (from onset of first non-Raynaud manifestation); 4) not eligible for or declining autologous hematopoietic stem-cell transplantation
- Idiopathic Inflammatory Myopathies (IIM) participants must have, 1) positivity for at least one myositis-specific antibody; 2) active myositis or presence of ILD defined by clinically relevant pulmonary involvement despite treatment with at least 2 lines of standard therapy; 3) disease duration ≥ 6 months
Exclusion Criteria:
- Diagnosis of a non-rheumatic autoimmune disease requiring therapeutic or investigational immune therapy or modulation (e.g., neuropathy requiring IVIg, Multiple Sclerosis). Milder autoimmune conditions requiring replacement or exocrine functional therapies are acceptable (e.g., Type 1 diabetes, Celiac Disease, Autoimmune Thyroid Disease if on stable treatment for at least 6 months).
- History of any pre-existing liver disease, including cirrhosis, acute liver disease, or chronic liver disease (unless considered stable for >6 months and required screening laboratory tests meet criteria).
- Severe unresolved cardiac disease.
- Estimated glomerular filtration rate (GFR) <30 mL/min/1.73 m2.
- Presence or history of active infections, including hepatitis B, hepatitis C, human immunodeficiency virus (HIV), Human T-lymphotropic virus (HTLV) or tuberculosis. Participants with laboratory evidence of active infection are excluded even in the absence of clinical evidence of active infection. Participants with mild skin and nail fungal infections are not excluded.
- Acute infection requiring systemic therapy or hospitalization within 30 days before screening.
- Invasive aspergillus, histoplasmosis, or coccidioidomycosis infection within one year prior to enrollment.
- Any history of malignancy in the 5 years before screening except for completely resected squamous or basal cell carcinoma of the skin.
- Primary or secondary immunodeficiency, including hypogammaglobulinemia.
- History or evidence of progressive multifocal leukoencephalopathy (PML) or other demyelinating disorders.
- Allergies to humanized monoclonal antibodies or severe post-treatment hypersensitivity reactions other than localized injection site reaction, to any biological molecule.
- Systemic corticosteroid therapy or adrenocorticotropic hormone (ACTH) use within 30 days prior to screening and within entire duration of screening period prior to beginning of study treatment, unless prescribed as background therapy.
- Intolerance of or contraindication to oral or IV corticosteroids.
- Treatment with other biologic or non-biologic immunosuppressant agents (e.g., anti-CD20 therapies, TNF inhibitors, azathioprine, cyclosporine, methotrexate, or mycophenolate) within 6 months prior to screening, unless prescribed as background therapy.
- The participant has taken another investigational drug within 3 months or 5-half-lives before the screening visit, whichever is longer, or any investigational drug that has depleted a cell type or line without recovery.
- Previous treatment with anti-CD19 agents, anti-CD38 agents, bispecific anti-CD19/CD3 T cell engaging therapies, adoptive T cell therapy or any prior gene therapy product.
- Received any form of stem cell transplant.
- Administration of live attenuated vaccine(s) within 12 weeks prior to and 12 weeks after the completion of DFI205 administration or any planned receipt during the study that cannot be delayed. Vaccinations should be up-to-date as per local clinical practice.
- Plasmapheresis within 3 months prior to first dose of DFI205
- Positive pregnancy test, presently breast-feeding, (female participants) or unwillingness to use highly effective contraceptive measures for the duration of the study and 6 months after discontinuation.
- Any condition, including the presence of relevant abnormalities in vital parameters or laboratory abnormalities, which places the subject at unacceptable risk if he/she were to participate in the study or confounds the ability to interpret data from the study.
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: Nicht randomisiert
- Interventionsmodell: Sequenzielle Zuweisung
- Maskierung: Keine (Offenes Etikett)
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
|---|---|
|
Experimental: Phase 1 Single Ascending Dose Escalation
Intravenous (IV) infusion of DFI205 at ascending dose levels. |
A bispecific monoclonal antibody that binds to both CD20 and CD40 receptors on cells. |
|
Experimental: Phase 2a Multi-Dose
DFI205 monthly IV infusions at the recommended Phase 2 dose |
A bispecific monoclonal antibody that binds to both CD20 and CD40 receptors on cells. |
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
To evaluate the initial safety and tolerability of DFI205 in adults with SARDs
Zeitfenster: Up to 1 year post-dosing
|
Numbers and types of all adverse events (AEs) and serious adverse events (SAEs) |
Up to 1 year post-dosing
|
|
To monitor immune reconstitution after completion of dosing with DFI205
Zeitfenster: Up to 1 year post-dosing
|
Time to normalized peripheral blood B cell counts compared to baseline. |
Up to 1 year post-dosing
|
|
To monitor immune response to DFI205
Zeitfenster: Up to 1 year post-dosing
|
Number of participants with anti-drug antibody development. |
Up to 1 year post-dosing
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
To evaluate the ability of DFI205 to induce an objective response in adults with RA
Zeitfenster: 24 weeks post-dosing
|
Overall Response Rate (ORR) measured by proportion of participants achieving either low-disease activity (DAS28-CRP ≤ 3.2, DAS28-ESR ≤3.2, SDAI≤11, CDAI≤10) or remission criteria (DAS28-CRP < 2.6, DAS28-ESR <2.6, SDAI ≤3.3, CDAI ≤ 2.8,Boolean 2.0 remission criteria) combined |
24 weeks post-dosing
|
|
To evaluate the ability of DFI205 to induce an objective response in adults with SLE
Zeitfenster: 24 weeks post-dosing
|
Overall Response Rate (ORR) measured by fulfillment of DORIS remission criteria |
24 weeks post-dosing
|
|
To evaluate the ability of DFI205 to induce an objective response in adults with SSc
Zeitfenster: 24 weeks post-dosing
|
Overall Response Rate (ORR) measured by proportion of participants achieving either modified Rodnan Skin Score (mRSS) decrease of >5 points and ≥ 25% decrease from baseline or no progression of interstitial lung disease (ILD progression defined as FVC decline >10%, or 5-10% plus worsening respiratory symptoms or HRCT progression) combined |
24 weeks post-dosing
|
|
To evaluate the ability of DFI205 to induce an objective response in adults with IIM
Zeitfenster: 24 weeks post-dosing
|
Overall Response Rate (ORR) measured by achievement of major response (ACR/EULAR 2016 Myositis Response Criteria Total Improvement Score ≥ 60) |
24 weeks post-dosing
|
Andere Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
To evaluate the ability of DFI205 to reduce disease activity in adults with RA
Zeitfenster: 24 weeks post-dosing
|
Change in tender joint count (TJC28) compared to baseline |
24 weeks post-dosing
|
|
To evaluate the ability of DFI205 to reduce disease activity in adults with RA
Zeitfenster: 24 weeks post-dosing
|
Change in swollen joint count (SJC28) compared to baseline |
24 weeks post-dosing
|
|
To evaluate the ability of DFI205 to reduce disease activity in adults with SLE
Zeitfenster: 24 weeks post-dosing
|
Change in British Isles Lupus Assessment Group (BILAG-2004) score compared to baseline |
24 weeks post-dosing
|
|
To evaluate the ability of DFI205 to reduce disease activity in adults with SSc
Zeitfenster: 24 weeks post-dosing
|
Change in mRSS (0=no thickening, 3=severe thickening) compared to baseline |
24 weeks post-dosing
|
|
To evaluate the ability of DFI205 to reduce disease activity in adults with IIM
Zeitfenster: 24 weeks post-dosing
|
Change in creatine phosphokinase (CPK) compared to baseline |
24 weeks post-dosing
|
|
To evaluate the ability of DFI205 to reduce disease activity in adults with IIM
Zeitfenster: 24 weeks post-dosing
|
Change in muscle strength (MMT8 score) compared to baseline |
24 weeks post-dosing
|
|
To evaluate change in erythrocyte sedimentation rate (ESR) as a potential biomarker of progression/treatment response to DFI205 over the course of the study.
Zeitfenster: Up to 1 year post-dosing
|
Up to 1 year post-dosing
|
|
|
To evaluate change in C-reactive protein (CRP) as a potential biomarker of progression/treatment response to DFI205 over the course of the study.
Zeitfenster: Up to 1 year post-dosing
|
Up to 1 year post-dosing
|
|
|
To evaluate change in interleukin-6 (IL-6) as a potential biomarker of progression/treatment response to DFI205 over the course of the study.
Zeitfenster: Up to 1 year post-dosing
|
Up to 1 year post-dosing
|
|
|
To evaluate change in tumor necrosis factor-alpha (TNF-α) as a potential biomarker of progression/treatment response to DFI205 over the course of the study.
Zeitfenster: Up to 1 year post-dosing
|
Up to 1 year post-dosing
|
|
|
To investigate the pharmacokinetics of DFI205
Zeitfenster: Up to 1 year post-dosing
|
Blood samples will be collected to quantitate serum concentrations of DFI205 |
Up to 1 year post-dosing
|
|
To investigate the pharmacodynamics of DFI205 in blood
Zeitfenster: Up to 1 year post-dosing
|
Proportions of immune cell subsets in blood by FACS analysis over the course of the study. |
Up to 1 year post-dosing
|
|
To investigate the secondary lymphoid system pharmacodynamics of DFI205
Zeitfenster: Up to 1 year post-dosing
|
Proportions of disease-specific lymph node cell populations over the course of the study. |
Up to 1 year post-dosing
|
|
To investigate soluble CD40 pharmacodynamics of DFI205
Zeitfenster: Up to 1 year post-dosing
|
Soluble CD40 receptor/ligand blood concentrations over the course of the study treatments. |
Up to 1 year post-dosing
|
Mitarbeiter und Ermittler
Sponsor
Ermittler
- Hauptermittler: Georg Schett, M.D., University of Erlangen-Nürnberg
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Geschätzt)
Primärer Abschluss (Geschätzt)
Studienabschluss (Geschätzt)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Zusätzliche relevante MeSH-Bedingungen
- Erkrankungen des Bewegungsapparates
- Erkrankungen des Nervensystems
- Muskelerkrankungen
- Neuromuskuläre Erkrankungen
- Arthritis
- Gelenkerkrankungen
- Rheumatische Erkrankungen
- Bindegewebserkrankungen
- Autoimmunerkrankungen
- Erkrankungen des Immunsystems
- Hautkrankheiten
- Haut- und Bindegewebserkrankungen
- Lupus erythematodes, systemisch
- Sklerodermie, systemisch
- Arthritis, Rheuma
- Myositis
Andere Studien-ID-Nummern
- 2026TXSARD01
- 2026-526672-24-00 (Ctis)
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .